Michael Kuettel
Overview
Explore the profile of Michael Kuettel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
963
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaishampayan U, Heilbrun L, Vaishampayan N, Harper F, Shi D, Smith D, et al.
Int J Radiat Oncol Biol Phys
. 2023 Nov;
118(5):1472-1480.
PMID: 37981040
Purpose: Bladder cancer is predominantly a disease of older individuals. Concurrent chemotherapy and radiation is a bladder-sparing strategy for management of muscle-invasive bladder cancer; however, many patients are not candidates...
2.
Hussein A, Shabir U, Mahmood A, Harrington G, Khan M, Ahmad A, et al.
Urol Oncol
. 2023 Nov;
41(12):483.e21-483.e26.
PMID: 37945390
Introduction: We sought to investigate the impact of National Comprehensive Cancer Network (NCCN)-compliant multidisciplinary conference on the uptake of active surveillance (AS) among eligible patients with prostate cancer. Methods: Retrospective...
3.
Hussein A, Iqbal U, Jing Z, Ramahi Y, Houenstein H, Newman S, et al.
J Natl Compr Canc Netw
. 2023 Apr;
21(4):359-365.e4.
PMID: 37015336
Background: We sought to investigate the impact of an NCCN-compliant multidisciplinary conference on treatment decisions of patients with localized prostate cancer. Methods: A retrospective review of our quality assurance localized...
4.
Emam A, Hermann G, Attwood K, Ji W, James G, Kuettel M, et al.
Prostate
. 2021 Jan;
81(4):223-230.
PMID: 33471385
Objective: To compare the oncologic outcomes of radical prostatectomy (RP) versus external beam radiotherapy (EBRT) ± androgen deprivation therapy for primary treatment of high risk localized prostate cancer (CaP). Methods:...
5.
Hsu I, Rodgers J, Shinohara K, Purdy J, Michalski J, Roach 3rd M, et al.
Int J Radiat Oncol Biol Phys
. 2020 Nov;
110(3):700-707.
PMID: 33186617
Purpose: To report the long-term outcome of patients with prostate cancer treated with external beam radiation therapy and high dose rate (HDR) brachytherapy from a prospective multi-institutional trial conducted by...
6.
Hepel J, Heron D, Mundt A, Yashar C, Feigenberg S, Koltis G, et al.
J Oncol Pract
. 2017 Mar;
13(5):e516-e521.
PMID: 28301278
Purpose: Accreditation based on peer review of professional standards of care is essential in ensuring quality and safety in administration of radiation therapy. Traditionally, medical chart reviews have been performed...
7.
Mohler J, Armstrong A, Bahnson R, DAmico A, Davis B, Eastham J, et al.
J Natl Compr Canc Netw
. 2016 Jan;
14(1):19-30.
PMID: 26733552
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease...
8.
Ettinger D, Kuettel M, Malin J, McClure J, Smith M, Zelenetz A, et al.
J Natl Compr Canc Netw
. 2015 May;
13(5 Suppl):640-2.
PMID: 25995417
Much has changed in the treatment of cancer since the first NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) were rolled out for 8 different tumor types in November 1996....
9.
Mohler J, Kantoff P, Armstrong A, Bahnson R, Cohen M, DAmico A, et al.
J Natl Compr Canc Netw
. 2014 May;
12(5):686-718.
PMID: 24812137
Prostate cancer has surpassed lung cancer as the most common cancer in men in the United States. The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management...
10.
Mohler J, Kantoff P, Armstrong A, Bahnson R, Cohen M, DAmico A, et al.
J Natl Compr Canc Netw
. 2013 Dec;
11(12):1471-9.
PMID: 24335682
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical...